•
Dec 31, 2019

InspireMD Q4 2019 Earnings Report

Reported a revenue increase driven by CGuard EPS sales, offset by a decrease in MGuard Prime EPS sales and increased operating expenses due to separation agreement payments.

Key Takeaways

InspireMD reported a 23.2% increase in revenue for Q4 2019, driven by a 31.4% increase in CGuard EPS sales. However, this was partially offset by a decrease in MGuard Prime EPS sales and an increase in operating expenses, resulting in a net loss of $2,557,000, or $0.57 per share.

Revenue increased by 23.2% to $1,013,000 compared to Q4 2018.

CGuard EPS sales increased by 31.4% to $921,000.

Net loss for the quarter was $2,557,000, or $0.57 per share.

Gross margin decreased to 25.6% from 27.6% in the same period in 2018.

Total Revenue
$1.01M
Previous year: $822K
+23.2%
EPS
-$8.55
Previous year: -$37.5
-77.2%
CGuard EPS Sales Growth
31.4%
Gross Profit
$259K
Cash and Equivalents
$5.51M
Total Assets
$14.1M

InspireMD

InspireMD

InspireMD Revenue by Segment